Q-omics provides the consensus-scored HNRNPAB profile across patient tissues and cancer cell-line models. HNRNPAB expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, HNRNPAB is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, HNRNPAB protein abundance shows 27,263 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where HNRNPAB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPAB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPAB survival associations across molecular data types. HNRNPAB RNA expression shows survival associations in the most cancer types (29), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPAB RNA expression–survival associations across cancer types. High HNRNPAB expression shows unfavorable associations in LUAD, KIRP, KICH, UVM and UCS, but favorable associations in READ. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for HNRNPAB RNA expression.
This table summarizes HNRNPAB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HNRNPAB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPAB shows higher tumor expression in KIRC, LIHC, LUAD, LUSC, KIRP and STAD. The KIRC box plot shows higher HNRNPAB RNA expression in tumor versus normal tissue (log2 FC = +0.694, t-test p < 0.001).
This table shows molecular features associated with HNRNPAB in patient tissues and cancer cell lines. In patient samples, HNRNPAB shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HNRNPAB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
